Grevel J, Thomas P, Whiting B
Department of Materia Medica, University of Glasgow, Scotland.
Clin Pharmacokinet. 1989 Jul;17(1):53-63. doi: 10.2165/00003088-198917010-00005.
The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential hypertension receiving multiple oral doses of bisoprolol 10 or 20mg for 3 months; group II, patients with different degrees of renal impairment and healthy controls; and group III, patients with different types of hepatic impairment and healthy controls. Patients and controls in groups II and III received only a single oral dose of bisoprolol 10mg. The 3 data sets were analysed separately, using a non-linear mixed effects model (the NONMEM program). A 2-compartment pharmacokinetic model with first-order absorption described the data adequately. The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively. Plasma clearance was related to age in group I, to serum creatinine in group II and to aspartate transaminase activity in group III. The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I. The analysis predicted that progressive increases in serum creatinine or aspartate transaminase activity will result in only a 50% reduction of clearance.
在比索洛尔的临床研发过程中,采用群体药代动力学分析技术研究其剂量浓度关系的变异性。在3个不同人群中研究了人口统计学因素对清除率变异性的影响:第一组,患有原发性高血压的患者(包括老年组),接受多次口服10或20mg比索洛尔,持续3个月;第二组,不同程度肾功能损害的患者和健康对照者;第三组,不同类型肝功能损害的患者和健康对照者。第二组和第三组的患者及对照者仅接受单次口服10mg比索洛尔。使用非线性混合效应模型(NONMEM程序)分别分析这3组数据集。具有一级吸收的二室药代动力学模型能充分描述数据。这3个人群的中央室容积、稳态分布容积和吸收速率常数的典型值分别为:第一组,68L、235L和0.7h-1;第二组,28L、179L和0.3h-1;第三组,55L、256L和0.4h-1。第一组中血浆清除率与年龄有关,第二组中与血清肌酐有关,第三组中与天冬氨酸转氨酶活性有关。对于第一组中50岁的患者,清除率和消除半衰期的68%置信区间分别为8.2至21.5L/h和7.6至19.7h。分析预测,血清肌酐或天冬氨酸转氨酶活性的逐渐增加只会导致清除率降低50%。